Stock NSB NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials NeuroScientific Biopharmaceuticals Limited

Equities

NSB

AU0000012973

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:05 2024-04-29 am EDT 		5-day change 1st Jan Change
0.052 AUD +8.33% Intraday chart for NeuroScientific Biopharmaceuticals Limited 0.00% +18.18%
Mar. 20 NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6% MT
Feb. 27 NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023
Capitalization 1 10.67 14.89 48.06 25.82 11.48
Enterprise Value (EV) 1 6.06 11.61 33.9 18.61 6.566
P/E ratio -6.25 x -5.18 x -15.1 x -2.47 x -10.7 x
Yield - - - - -
Capitalization / Revenue 315 x - 50.1 x - 2.32 x
EV / Revenue 179 x - 35.4 x - 1.33 x
EV / EBITDA -3.88 x -4.02 x -10.6 x -1.78 x -5.9 x
EV / FCF -7.27 x -9.24 x -22.7 x -6.05 x -3.33 x
FCF Yield -13.8% -10.8% -4.41% -16.5% -30%
Price to Book 2.11 x 4.08 x 3.29 x 4.68 x 2.45 x
Nbr of stocks (in thousands) 73,581 78,385 143,472 143,472 143,472
Reference price 2 0.1450 0.1900 0.3350 0.1800 0.0800
Announcement Date 8/30/19 8/28/20 8/27/21 8/29/22 8/25/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.0289 0.0338 - 0.9588 - 4.953
EBITDA 1 -0.8889 -1.562 -2.885 -3.203 -10.44 -1.114
EBIT 1 -0.9318 -1.618 -2.941 -3.265 -10.5 -1.171
Operating Margin -3,227.03% -4,779.14% - -340.53% - -23.65%
Earnings before Tax (EBT) 1 -0.9314 -1.659 -2.869 -3.178 -10.44 -1.069
Net income 1 -0.9314 -1.659 -2.869 -3.178 -10.44 -1.069
Net margin -3,225.59% -4,900.92% - -331.45% - -21.58%
EPS 2 -0.0301 -0.0232 -0.0367 -0.0221 -0.0727 -0.007448
Free Cash Flow 1 -0.149 -0.8336 -1.256 -1.494 -3.076 -1.971
FCF margin -515.89% -2,462.8% - -155.84% - -39.79%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/31/18 8/30/19 8/28/20 8/27/21 8/29/22 8/25/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 0.1 4.61 3.29 14.2 7.22 4.91
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.15 -0.83 -1.26 -1.49 -3.08 -1.97
ROE (net income / shareholders' equity) -147% -57.3% -65.9% -34.8% -104% -20.9%
ROA (Net income/ Total Assets) -83.9% -34.1% -41.5% -22% -58.2% -11.2%
Assets 1 1.11 4.867 6.913 14.46 17.93 9.508
Book Value Per Share 2 0.0200 0.0700 0.0500 0.1000 0.0400 0.0300
Cash Flow per Share 2 0 0.0600 0.0400 0.1000 0.0500 0.0300
Capex - 0.02 0 0.03 0 -
Capex / Sales - 56.37% - 3.12% - -
Announcement Date 8/31/18 8/30/19 8/28/20 8/27/21 8/29/22 8/25/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED Stock NeuroScientific Biopharmaceuticals Limited
+18.18% 4.53M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.18% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.75% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.47% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.71% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.39% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.90% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.76% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NSB Stock
  4. Financials NeuroScientific Biopharmaceuticals Limited